Eli Lilly
Interim analysis fails to show benefits for Lilly’s abemaciclib in advanced breast cancer
August 10, 2016Research and Development Eli Lilly, abemaciclib, breast cancer
Eli Lilly has announced that, after a pre-planned interim analysis for their Phase III MONARCH2 trial, investigators have decided to …
John Lechleiter to step down as Lilly CEO
July 27, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, John Lechleiter
Eli Lilly has announced that CEO John Lechleiter is set to retire, with David Ricks to assume the role as …
Eli Lilly Q2 2016 results surpass estimates
July 27, 2016Research and Development, Sales and Marketing Eli Lilly, financial report
Eli Lilly has released its financial report for the second quarter of 2016, noting a number of promising results. The …
Lilly, Boehringer Ingelheim to jointly study combination therapy for breast cancer
July 14, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, breast cancer, combination therapy, drug trial
US drug major Eli Lilly (NYSE: LLY) and Boehringer Ingelheim said they will jointly initiate early combination trials in breast cancer. The …
Eli Lilly says FDA panel backs approval of Jardiance for cardiovascular indication
June 30, 2016Research and Development, Sales and Marketing Eli Lilly, cardiovascular, diabetes, jardiance
US drugmaker Eli Lilly (NYSE: LLY) said a US regulatory panel has backed its Jardiance (empagliflozin) for reducing cardiovascular death …
German Supreme Court grants Lilly appeal to block Alimta generics
June 15, 2016Research and Development, Sales and Marketing Actavis, Alimta, Eli Lilly
Eli Lilly (NYSE: LLY) has announced that it has been granted an appeal by the German Federal Supreme Court, in …
FDA approves Lilly/Boehringer Ingelheim type-2 diabetes drug
June 1, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, diabetes, jentadueto, jentadueto xr, lilly, partnership, type 2, type-2
The US Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release) tablets for the …
Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance
May 26, 2016Research and Development, Sales and Marketing Cancer Drugs Fund, Eli Lilly, NICE, lung cancer
The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat …
Eli Lilly showcases emerging pipeline to investors
May 25, 2016Research and Development Eli Lilly, investors, lilly, pipeline, research and development
Eli Lilly and Co (NYSE: LLY) has showcased its emerging pipeline to potential investors, highlighting its potential to launch 20 …
Nice recommends three drugs to treat diabetes
May 25, 2016Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes
The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …
FDA issues warning about rare, but serious, side effect in Lilly antipsychotic drug
May 12, 2016Medical Communications, Sales and Marketing Eli Lilly, FDA, anti-psychotic, boxed warning, lilly, olanzapine, skin condition
The US Food and Drug Administration (FDA) has issued a new warning to all drug labels for Eli Lilly’s antipsychotic …
Eli Lilly’s cancer drug candidate scores FDA priority review
May 5, 2016Eli Lilly, US FDA, oncology, regulation
US drugmaker Eli Lilly (NYSE: LLY) said the US Food and Drug Administration (FDA) has granted priority review for its …
NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis
April 27, 2016Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation
The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …
Eli Lilly Q1 earnings miss estimates, ups FY view; shares drop 2%
April 27, 2016Research and Development, Sales and Marketing Eli Lilly, FY, Q1, earnings, revenue, sales
Shares in US drugmaker Eli Lilly (NYSE: LLY) dropped to close down over 2% Tuesday after the company posted first-quarter …
Eli Lilly gets European marketing authorisation for psoriasis drug
April 26, 2016EC, EU, Eli Lilly, drug trial, psoriasis, regulation
US pharma firm Eli Lilly and Co (NYSE: LLY) on Tuesday said the European Commission backed marketing authorisation for its …
Latest content
Five Facts about cardiovascular disease
